Nitorum Capital L.P. Makes New $4.42 Million Investment in Qiagen N.V. $QGEN

Key Points

• Nitorum Capital L.P. has acquired 110,000 shares in Qiagen N.V. during the first quarter, with an investment valued at approximately $4.4 million, making Qiagen about 0.6% of their portfolio.
• Multiple institutional investors have also recently purchased shares in Qiagen, increasing overall institutional ownership to 70%.
• Analysts currently have a consensus rating of "Hold" on Qiagen, with an average price target of $49.69, reflecting a mixed outlook on the company's stock.

Nitorum Capital L.P. bought a new position in shares of Qiagen N.V. (NYSE:QGEN - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 110,000 shares of the company's stock, valued at approximately $4,416,000. Qiagen accounts for about 0.6% of Nitorum Capital L.P.'s investment portfolio, making the stock its 28th largest holding.

A number of other institutional investors also recently bought and sold shares of the company. Wellington Management Group LLP raised its stake in Qiagen by 12.2% during the first quarter. Wellington Management Group LLP now owns 24,438,441 shares of the company's stock worth $972,191,000 after purchasing an additional 2,656,136 shares during the period. Deutsche Bank AG raised its stake in Qiagen by 57.5% during the first quarter. Deutsche Bank AG now owns 4,491,131 shares of the company's stock worth $180,319,000 after purchasing an additional 1,639,621 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Qiagen by 3,030.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,470,728 shares of the company's stock worth $179,501,000 after purchasing an additional 4,327,934 shares during the period. Allspring Global Investments Holdings LLC raised its stake in Qiagen by 4.7% during the first quarter. Allspring Global Investments Holdings LLC now owns 2,445,641 shares of the company's stock worth $96,605,000 after purchasing an additional 109,481 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Qiagen during the fourth quarter worth about $95,746,000. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Stock Down 1.8%

Shares of NYSE:QGEN traded down $0.84 during trading hours on Wednesday, reaching $46.20. The stock had a trading volume of 271,757 shares, compared to its average volume of 1,380,600. Qiagen N.V. has a 1 year low of $37.63 and a 1 year high of $51.88. The firm's 50 day moving average is $48.62 and its 200-day moving average is $44.50. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. The stock has a market capitalization of $10.27 billion, a price-to-earnings ratio of 27.30, a P/E/G ratio of 2.51 and a beta of 0.64.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, meeting analysts' consensus estimates of $0.60. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The company had revenue of $533.54 million for the quarter, compared to the consensus estimate of $523.97 million. During the same period in the prior year, the firm posted $0.55 EPS. The company's quarterly revenue was up 7.7% compared to the same quarter last year. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Research analysts predict that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Wall Street Zen downgraded shares of Qiagen from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. Bank of America boosted their price target on shares of Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a research note on Thursday, June 26th. UBS Group boosted their price target on shares of Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a research note on Thursday, August 7th. Cowen reissued a "hold" rating on shares of Qiagen in a research note on Thursday, August 7th. Finally, Barclays started coverage on shares of Qiagen in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price target on the stock. Three investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Qiagen currently has a consensus rating of "Hold" and a consensus target price of $49.69.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.